Eli Lilly and Co. and Purdue University entered a strategic five-year agreement, under which Lilly will provide as much as $52 million to develop improved delivery of injectable medicines to reduce pain, number of injections, and improve patient compliance.The collaboration will also focus on developing predictive models for clinical trials that reduce risks associated with investing in drug development and more effectively predict the outcome of new therapies in humans.
 
“Purdue has enjoyed a long history of engagement with Lilly. Now Lilly and Purdue University are entering into a new level of collaboration that will move us forward in areas core to both institutions,” said Purdue President Mitch Daniels. “Our investment on campus in the life sciences announced in 2016 is leading to just the types of impact we hoped to effect.”
 
“The biomedical revolution is upon us, but harnessing its full potential will require strong collaboration between academic research centers and industry partners,” said David Ricks, Lilly’s chairman, president and chief executive officer. “We look forward to expanding our relationship with Purdue as we work together to discover breakthrough solutions for patients.”
 
The collaboration aims to expand to other areas to further leverage the range of expertise at the two institutions.Purdue researchers from the natural and physical sciences, engineering and veterinary medicine will contribute to the interdisciplinary collaboration with Lilly researchers.